The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment.

Cell Mol Immunol · 2023 · PMC10203371 · PMID 36928371

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

48.2% in the placebo arm) reached the primary endpoint of achieving EASI50 at week 12, but the results failed to reach statistical significance [ 88 ].

also in 6,035 other papers

failed to reach significanceno p-value reported

Another IL-33 inhibitor, itepekimab (REGR3500), failed to reach significance in a phase II clinical trial that was terminated owing to a lack of efficacy ( NCT03736967 ) [ 133 ], while the results of another phase II monotherapy trial ( NCT03738423 ) have been submitted and are awaiting quality control before publication.

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.